Immunopathogenesis of psoriasis

Australasian Journal of Dermatology

Volumn 47, Issue 3, 2006, Pages 151-159

  Lee, Michael R ^a   Cooper, Alan J ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Antigen presenting cell; Interferon ; Langerhans cell; T cell; Tumour necrosis factor

Indexed keywords

B7 ANTIGEN; CD18 ANTIGEN; CD28 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOKINE; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

CELL ACTIVATION; CELL MATURATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LANGERHANS CELL; PSORIASIS; REVIEW; SKIN DISEASE; T LYMPHOCYTE ACTIVATION;

HUMANS; IMMUNITY, CELLULAR; KERATINOCYTES; PSORIASIS; T-LYMPHOCYTES;

EID: 33745764047     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/j.1440-0960.2006.00262.x     Document Type: Review

References (65)

1. Greaves MW, Weinstein GD. Treatment of psoriasis. N. Engl. J. Med. 1995; 332: 581-8.
2. Jobling RG. Psoriasis: a preliminary questionnaire study of sufferers' subjective experience. Clin. Exp. Dermatol. 1976; 1: 233-6.
3. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol. Clin. 1996; 14: 485-96.
4. Fried RG, Friedman S, Paradis C, Hatch M, Lynfield Y, Duncanson C, Shalita A. Trivial or terrible? The psychosocial impact of psoriasis. Int. J. Dermatol. 1995; 34: 101-5.
5. Gupta M, Gupta AK. Quality of life of psoriasis patients. J. Eur. Acad. Dermatol. Venereol. 2000; 14: 241-2.
6. Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J. Eur. Acad. Dermatol. Venereol. 2000; 14: 267-71.
7. Wahl A, Lodge JH, Wiklund I, Hanestad BR. The burden of psoriasis: a study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J. Am. Acad. Dermatol. 2000; 43: 803-8.
8. Griffiths CEM. Immunotherapy for psoriasis: from serendipity to selectivity. Lancet 2002; 359: 279-80.
9. Henseler T. The genetics of psoriasis. J. Am. Acad. Dermatol. 1997; 37: S1-11.
10. Farber EM, Nall ML. Genetics of psoriasis: twin studies. In: Farber EM, Cox AJ (eds). Psoriasis: Proceedings from the International Symposium. Stanford, CA: Stanford University Press, 1971; 7-13.
11. Brandrup F, Hauge M, Henningsen K, Eriksen B. Psoriasis in an unselected series of twins. Arch. Dermatol. 1978; 114: 874-8.
12. Duffy DL, Spelman LS, Martin NG. Psoriasis in Australian twins. J. Am. Acad. Dermatol. 1993; 29: 428-34.
13. Rosenberg EW, Noah PW, Skinner RB. Psoriasis is a visible manifestation of the skin's defence against micro-organisms. J. Dermatol. 1994; 21: 375-81.
14. Baker BS, Bokth S, Powles A. Group A streptococcal antigen-specific T-lymphocytes in guttate psoriasis lesions. Br. J. Dermatol. 1993; 128: 493-9.
15. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L. Psoriasis: a T-cell mediated autoimmune disease induced by streptococcal superantigens? Immunol. Today 1995; 16: 145-9.
16. Mahoney SE, Duvic M, Nickoloff BJ, Minshall M, Smith LC, Griffiths CEM, Paddock SW, Lewis DE. HIV transcripts in HIV-related psoriasis and Kaposi's sarcoma lesions. J. Clin. Invest. Dermatol. 1991; 88: 174-85.
17. Sigmundsdottir H, Sigurgeirsson B, Troye-Blomberg M, Good MF. Circulating T-cells of patients with active psoriasis respond to streptococcal M-peptides sharing sequences with human epidermal keratins. Scand. J. Immunol. 1997; 45: 688-97.
18. Favre M, Orth G, Majewski S, Baloul S, Pura A, Jablonska S. Psoriasis: a possible reservoir for human papillomavirus type 5, the virus associated with carcinomas of epidermodysplasia verruciformis. J. Invest. Dermatol. 1998; 110: 311-17.
19. Naukkarinen A, Nickoloff BJ, Farber EM. Quantification of cutaneous sensory nerves and their substance P content in psoriasis. J. Invest. Dermatol. 1989; 92: 126-9.
20. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 2002; 46: 1-23.
21. Trowsdale J, Campbell RD. Complexity in the major histocompatibility complex. Eur. J. Immunogenet. 1992; 19: 45-55.
22. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 1996; 183: 2533-40.
23. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541-7.
24. Tivol EA, Boyd SD, McKeon S, Borriello F, Nickerson P, Strom TB, Sharpe AH. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4 deficient mice. J. Immunol. 1997; 158: 5091-4.
25. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch. Dermatol. 2002; 138: 657-63.
26. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, Meyer zum Büschenfelde KH, Fleischer B. T cells involved in psoriasis vulgaris belong to the Th-1 subset. J. Invest. Dermatol. 1994; 102: 145-9.
27. Bonfiati C, Ameglio F. Cytokines in psoriasis. Int. J. Dermatol. 1999; 38: 241-51.
28. Yawalkar N, Karlen S, Hunger R, Brand CU, Braathen LR. Expression of interleukin-12 is increased in psoriatic skin. J. Invest. Dermatol. 1998; 111: 1053-7.
29. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG. The majority of epidermal T-cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2 and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 1999; 113: 752-9.
30. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 1996; 98: 1878-87.
31. Huang NN, Bonish BK, Chaturvedi V, Qin JZ, Nickoloff BJ. Keratinocyte CDw60 expression is modulated by both a Th-1 type cytokine IFN-gamma and Th-2 cytokines IL-4 and IL-13: relevance to psoriasis. J. Invest. Dermatol. 2001; 116: 305-12.
32. Reich K, Westphal G, Schulz T, Muller M, Zipprich S, Fuchs T, Hallier E, Neumann C. Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolising enzymes in psoriasis. J. Invest. Dermatol. 1999; 113: 214-20.
33. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type-1 cell-mediated response. J. Invest. Dermatol. 1993; 101: 701-5.
34. Picker LJ, Kishimoto TK, Smith CW, Warnock RA, Butcher EC. ELAM-1 is an adhesion molecule for skin-homing T cells. Nature 1991; 349: 796-9.
35. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PGSL-1 expressed on skin homing T cells. Nature 1997; 389: 978-81.
36. Groves RW, Ross E, Barker JN, Ross JS, Camp RD, MacDonald DM. Effect of in vivo interleukin-1 on adhesion molecule expression in normal human skin. J. Invest. Dermatol. 1992; 98: 384-7.
37. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N. Engl. J. Med. 1999; 341: 1817-28.
38. Terajima S, Higaki M, Igarashi Y, Nogita T, Kawashima M. An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis. Arch. Dermatol. Res. 1998; 290: 246-52.
39. O'Doherty U, Steinman RM, Peng M, Cameron PU, Gezelter S, Kopeloff I, Swiggard WJ, Pope M, Bhardwaj N. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte conditioned medium. J. Exp. Med. 1993; 178: 1067-76.
40. Schottelius AJG, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK. Biology of tumour necrosis factor-α: implications for psoriasis. Exp. Dermatol. 2004; 13: 193-222.
41. Barnes PJ, Karin M. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory disease. N. Engl. J. Med. 1997; 336: 1066-72.
42. Detmar M, Imcke E, Ruszczak Z, Orfanos CE. Effect of recombinant tumor necrosis factor-alpha on cultured microvascular endothelial cells derived from human dermis. J. Invest. Dermatol. 1990; 95: 219-22.
43. Griffiths CE, Voorhees JJ, Nickoloff BJ. Characterisation of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J. Am. Acad. Dermatol. 1989; 20: 617-29.
44. Leszczynski D. Interleukin-1 alpha inhibits the effects of gamma-interferon and tumor necrosis factor alpha on the expression of the major histocompatibility antigens by the rat endothelium. Am. J. Pathol. 1990; 136: 229-37.
45. Nickoloff BJ. The cytokine network in psoriasis. Arch. Dermatol. 1991; 127: 871-84.
46. Wakefield PE, James WD, Samlaska CP, Meltzer MS. Tumor necrosis factor. J. Am. Acad. Dermatol. 1991; 24: 675-85.
47. De Boer O, Wakelkamp I, Pals S, Claessen N, Bos J, Das P. Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin. Arch. Dermatol. Res. 1994; 286: 304-11.
48. Onuma S. Immunohistochemical studies of infiltrating cells in early and chronic lesions of psoriasis. J. Dermatol. 1994; 21: 223-32.
49. Kimber I, Cumberbatch M, Dearman RJ, Bhushan M, Griffiths CEM. Cytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization. Br. J. Dermatol. 2000; 142: 401-12.
50. Young HS, Summers AM, Bhushan M, Brenchley PEC, Griffiths CEM. Single nucleotide polymorphisms of vascular endothelial growth factor (VEGF) in psoriasis of early onset. J. Invest. Dermatol. 2004; 122: 209-15.
51. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003; 102: 161-8.
52. Nielsen HJ, Christensen IJ, Svendsen MN, Hansen U, Werther K, Brünner N, Petersen LJ, Kristensen JK. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm. Res. 2002; 51: 563-7.
53. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman AW, Berse B, Dvorak HF. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J. Exp. Med. 1994; 180: 1141-6.
54. Creamer D, Allen M, Jaggar R, Stevens R, Bicknell R, Barker J. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch. Dermatol. 2002; 138: 791-6.
55. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br. J. Dermatol. 1999; 141: 1054-60.
56. Detmar M. Evidence for vascular endothelial growth factor (VEGF) as a modifier gene in psoriasis. J. Invest. Dermatol. 2004; 122: 14-15.
57. Hancock GE, Kaplan G, Cohn ZA. Keratinocyte growth regulation by the products of immune cells. J. Exp. Med. 1988; 168: 1395-402.
58. Wang Y, Jensen PJ. Regulation of the level and glycosylation state of plasminogen activator inhibitor type 2 during human keratinocyte differentiation. Differentiation 1998; 63: 93-9.
59. Knopp J. Immunologic effects of interferon. J. Invest. Dermatol. 1990; 95: 72S-4S.
60. Barker JNW, Sarma V, Mitra S, Dixit VM, Nickoloff BJ. Marked synergism between tumour necrosis factor-alpha and interferon-gamma in regulation of keratinocyte-derived adhesion molecule and chemotactic factors. J. Clin. Invest. 1990; 85: 605-8.
61. Nickoloff BJ. Role of interferon-gamma in cutaneous trafficking of lymphocytes with emphasis on molecular and cellular adhesion events. Arch. Dermatol. 1988; 124: 1835-42.
62. Aggarwal BB, Natarajan K. Tumour necrosis factors: developments during the last decade. Eur. Cytokine Netw. 1996; 7: 93-124.
63. Gillitzer R, Ritter U, Spandau U, Goebeler M, Brocker EB. Differential expression of GRO-α and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo. J. Invest. Dermatol. 1996; 107: 778-82.
64. Detmar M, Yeo KT, Nagy JA, Van de Water L, Brown LF, Berse B, Elicker BM, Ledbetter S, Dvorak HF. Keratinocyte-derived vascular permeability factor (VEGF) is a potent mitogen for dermal microvascular endothelial cells. J. Invest. Dermatol. 1995; 105: 44-50.
65. Lebwohl M. Psoriasis. Lancet 2003; 361: 1197-204.